Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Gains from Sales and Divestitures: 2024-2025

  • Artiva Biotherapeutics' Gains from Sales and Divestitures was N/A to $205,360 in Q3 2025 from the same period last year, while for Sep 2025 it was $205,360, marking a year-over-year change of. This contributed to the annual value of $22,514 for FY2024, which is N/A change from last year.
  • Per Artiva Biotherapeutics' latest filing, its Gains from Sales and Divestitures stood at $205,360 for Q3 2025, which was up 324.32% from $48,397 recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Gains from Sales and Divestitures ranged from a high of $205,360 in Q3 2025 and a low of $22,514 during Q4 2024.
  • Its 2-year average for Gains from Sales and Divestitures is $92,090, with a median of $48,397 in 2025.